LIST OF FIGURES

Figure No.	Title	Page No.
Figure 2.1	Sub-endothelial changes during stellate cell activation accompanying liver injury	20
Figure 2.2	Pathways of stellate cell activation and resolution during liver injury	22
Figure 2.3	Biological actions of hepatic stellate cells (HSCs) during liver fibrogenesis and potential sites for therapeutic intervention	23
Figure 2.4	The renin-angiotensin-aldosterone and endothelin pathways and potential sites for therapy of liver fibrosis	70
Figure 2.5	Schematic representation of M6P-HSA conjugated carrier	72
Figure 2.6	The structure of multilamellar vesicles showing the organization of phospholipid bilayers and the encapsulation of lipophilic and hydrophilic compounds	74
Figure 2.7	Seven-step ladder for optimizing drug delivery systems	85
Figure 2.8	System with controllable input variables (X), uncontrollable input variables (U), transfer function (T), and output variables (Y)	89
Figure 2.9	Diagrammatic depiction of interaction. Unparallel lines in (b) describe the phenomenon of interaction between the levels of drug and polymer amount affecting drug dissolution	91
Figure 2.10	Quantitative factors and factor space	96
Figure 2.11	Diagrammatic representation of (a) 2^2 factorial design; (b) 2^3 factorial design	99
Figure 2.12	Diagrammatic representation of 2^3 factorial design with added center point	100
Figure 2.13	Different types of responses as functions of factor settings; (a) linear; (b) quadratic; (c) cubic	104
Figure 2.14	(a) A typical response surface plotted between a response variable, release exponent, and two factors, HPMC and sodium CMC, in case of mucoadhesive compressed matrices; (b) the corresponding contour plot	106
Figure 3.1	Calibration plot of RGZ in methanol	148
Figure 3.2	Calibration plot of RGZ in diffusion medium (50 mM HPBCD, 20 mM HEPES, pH 7.4)	150
Figure 3.3	Calibration plot of CDS in methanol	152
Figure 3.4	Calibration plot of CDS in diffusion medium (100 mM HPBCD, 20 mM HEPES, pH 7.4)	154
Figure 3.5	Calibration plot of RGZ in plasma by HPLC Method	157
Figure 3.6	Calibration plot of CDS in plasma by HPLC	160

	AND I BE COMPANY AND A COMPANY AND A COMPANY AND AND A COMPANY AND A COMPA	1 / 0
Figure 3.7	Calibration plot of D-Mannose	162
Figure 3.8	Calibration plot of Phosphorus	165
Figure 3.9	Calibration plot of Hydroxyproline	174
Figure 3.10	Calibration plot of Hyaluronic acid by ELISA method	177
Figure 4.1	Response surface plot and corresponding contour plot showing the influence of Drug:Lipid and Lipid:Chol ratio on PDE (a & b) and PR (c & d) for RGZ	205
Figure 4.2	Response surface plot and corresponding contour plot showing the influence of Drug:Lipid and Total solid:Hydration medium ratio on PDE (a & b) and PR (c & d) for RGZ	207
Figure 4.3	Response surface plot and corresponding contour plot showing the influence of Lipid:Chol and Total solid:Hydration medium ratio on PDE (a & b) and PR (c & d) for RGZ	209
Figure 4.4	Cube plots for PDE (a) and PR (b) representing the effects of three factors at a time for RGZ	210
Figure 4.5	Linear correlation plots of the experimental response values versus the predicted response values for PDE (a) and PR (b) for RGZ	212
Figure 4.6	Response surface plot and corresponding contour plot showing the influence of Drug: Lipid and Lipid: Chol ratio on PDE (a & b) and PR (c & d) for CDS	217
Figure 4.7	Response surface plot and corresponding contour plot showing the influence of Drug: Lipid and Total solid: Hydration medium ratio on PDE (a & b) and PR (c & d) for CDS	219
Figure 4.8	Response surface plot and corresponding contour plot showing the influence of Lipid: Chol and Total solid: Hydration medium ratio on PDE (a & b) and PR (c & d) for CDS	221
Figure 4.9	Cube plots for PDE (a) and PR (b) representing the effects of three factors at a time for CDS	222
Figure 4.10	Linear correlation plots of the experimental response values versus the predicted response values for PDE (a) and PR (b) for CDS	224
Figure 4.11	IR spectra of p-nitrophenyl-a-D-mannopyranoside	225
Figure 4.12	IR spectra of p-nitrophenyl-6-phospo-a-D-mannopyranoside	226
Figure 4.13	IR spectra of p-aminophenyl-6-phospo-a-D- mannopyranoside	226
Figure 4.14	IR spectra of HSA	227
Figure 4.15	IR spectra of M6P-HSA	227
Figure 4.16	IR spectra of Sebacic acid	228

Figure 4.17	IR spectra of Sebacic anhydride	228
Figure 4.18	IR spectra of DSPE	229
Figure 4.19	IR spectra of DSPE-Sebacic acid conjugate	229
Figure 4.20	Particle size and Zeta potential of unconjugated RGZ liposomes	230
Figure 4.21	Particle size and Zeta potential of M6P-HSA conjugated RGZ liposomes	230
Figure 4.22	Particle size and Zeta potential of unconjugated CDS liposomes	231
Figure 4.23	Particle size and Zeta potential of M6P-HSA conjugated CDS liposomes	231
Figure 4.24	TEM images of RGZ unconjugated (A) and RGZ M6P-HSA conjugated (B) liposomes	232
Figure 4.25	TEM images of CDS unconjugated (A) and CDS M6P-HSA conjugated (B) liposomes	232
Figure 4.26	DSC curve of RGZ plain drug (A) RGZ liposomes (B)	235
Figure 4.27	DSC curve of CDS plain drug (A) CDS liposomes (B)	235
Figure 4.28	X-ray diffractograms of RGZ plain drug and liposomal formulation	236
Figure 4.29	X-ray diffractograms of CDS plain drug and liposomal formulation	236
Scheme 4.1	TFH process stages in the preparation of RGZ liposomes	190
Scheme 4.2	TFH process stages in the preparation of CDS liposomes	193
Scheme 4.3	Synthesis of M6P-HSA	196
Scheme 4.4	M6P-HSA Conjugation to Liposomes	197
Figure 5.1	Comparative <i>in-vitro</i> drug diffusion profiles of plain RGZ and RGZ liposomal formulations	249
Figure 5.2	Comparative <i>in-vitro</i> drug diffusion profiles of plain CDS and CDS liposomal formulations	251
Figure 7.1	Representative histopathological images of liver tissues	273
Figure 7.2	Pharmacokinetic profiles of RGZ (different formulations) after single intravenous bolus injection in fibrotic rats	277
Figure 7.3	Pharmacokinetic profiles of CDS (different formulations) after single intravenous bolus injection in fibrotic rats	277
Figure 7.4	Complete tissue distribution of RGZ formulations after single intravenous bolus injection	280
Figure 7.5	Complete tissue distribution of CDS formulations after single intravenous bolus injection	280